Hamon Center for Therapeutic Oncology Research, Simmons Cancer Center, 6000 Harry Hines Boulevard, University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA.
Clin Chest Med. 2011 Dec;32(4):703-40. doi: 10.1016/j.ccm.2011.08.003. Epub 2011 Oct 7.
Lung cancer is a heterogeneous disease clinically, biologically, histologically, and molecularly. Understanding the molecular causes of this heterogeneity, which might reflect changes occurring in different classes of epithelial cells or different molecular changes occurring in the same target lung epithelial cells, is the focus of current research. Identifying the genes and pathways involved, determining how they relate to the biological behavior of lung cancer, and their utility as diagnostic and therapeutic targets are important basic and translational research issues. This article reviews current information on the key molecular steps in lung cancer pathogenesis, their timing, and clinical implications.
肺癌在临床上、生物学上、组织学上和分子上都是一种异质性疾病。理解这种异质性的分子原因，这可能反映了不同上皮细胞类型的变化或同一靶肺上皮细胞中发生的不同分子变化，是当前研究的重点。确定涉及的基因和途径，确定它们与肺癌的生物学行为的关系，以及它们作为诊断和治疗靶点的效用，是重要的基础和转化研究问题。本文综述了肺癌发病机制中关键分子步骤的最新信息，包括它们的时间顺序及其临床意义。
